PCSK9 Inhibitor Treatment for Patients With SPG5

NCT04101643 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Hereditary Spastic Paraplegia Type 5

Interventions

DRUG: evolocumab

Sponsor

First Affiliated Hospital of Fujian Medical University